Press Room

RDD Europe 2015

Start
Tuesday, May 05, 2015 - 00:00
End
Friday, May 08, 2015 - 00:00
Location: Nice, France
Booth Number: Table nr. 32

RDD Europe 2015 will be held from Tuesday 5th May until Friday 8th May 2015 at the Palais des Congres d'Antibes, Nice, France. Hovione will be present with a table (nr. 32), a presentation, a workshop and a set of posters.

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at RDD.

contact us button | Hovione

 

HOVIONE'S PRESENTATION
Optimized Composite Particles for API-independent Formulations with Enhanced Performance

Speaker: Eunice Costa, PhD (Scientist, Drug Product Development)
Date: Friday, May 5, 2015
Time: 8:30 AM

HOVIONE'S WORKSHOP
Trends in Inhalation Drug Development: Particle Engineering and Formulation Strategies

Speakers: Eunice Costa, PhD (Scientist, Drug Product Development)
                  Filipe Neves, PhD (Senior Scientist, Group Leader, Drug Product Development)
Date: Wednesday, May 6, 2015 
Time: tbd - afternoon from 2:00 to 6:00 PM

  • Introduction: This workshop addresses trends in particle engineering (PE) technologies, and formulation strategies to overcome problems during the development of inhalation drugs. Participants will gain insight into innovative approaches via comprehensive and diverse case studies chosen to illustrate the complexity of manufacturing processes. 
     
  • Workshop Content: Participants will learn the fundamentals of inhalation delivery, together with an overview of market trends and basic concepts associated with metered dose inhalation (MDI) and dry powder inhalation (DPI); for the latter platform, carrier based and composite particles based approaches will be emphasized. The impact of different particle engineering technologies on the final performance of both MDI and DPI (carrier based) products will be discussed. Case studies will link API properties (measured by cutting edge techniques) and formulation strategy, with the overall success of a given delivery platform. Lastly, DPI formulation based on spray dried composite particle approaches will be explored using case studies covering formulation development and process scale-up.
     
  • Outcome for Participants: The participants will gain insight into several innovative approaches, including a number of comprehensive and diverse case studies, which will illustrate the complex relationships linking inhaler design to particle engineering and formulation strategies.
     

POSTERS

Impact of the Size-Reduction Technology on the Performance of Suspension Pressurized Metered Dosed Inhalers: Benchmarking with Dry Powder Inhalers
Eunice Costa

Performance Optimization in Early DPI Development: Enabling High Dosage Drug Delivery to the Lungs Through Orifice-Based Aerosolization
João Fernandes

Benchmarking Gravimetric FSI vs ACI: Can We Expedite Aerodynamic Performance Evaluation for Composite Powders?
Isabel Lopes

Aerodynamic Performance of DPIs: Predicting the Impact of Carrier-Based Formulation Parameters
Filipa Maia

API Influence & Stability Assessment of Spray Dried Composite Particles
Cláudia Moura

Optimizing Trade-Offs Between Product Performance and Process Efficiency via Powder Rheology
Maria Palha

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024